Page contentsPage contentsKey factsDecisionRelated medicine informationKey facts Invented name Verzenios Active Substance abemaciclib Therapeutic area Oncology Decision number P/0367/2023 PIP number EMEA-002342-PIP05-23 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of prostate cancer Route(s) of administration All routes of administration Contact for public enquiries Eli Lilly and Company LimitedE-mail: EU_PAEDIATRIC@LILLY.COMTel. +44 1344382427 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 08/09/2023DecisionEMA/384130/2023 : EMA decision of 8 September 2023 on the granting of a product specific waiver for abemaciclib (Verzenios), (EMEA-002342-PIP05-23)Reference Number: EMA/384130/2023 English (EN) (190.84 KB - PDF)First published: 19/09/2024ViewRelated medicine informationVerzeniosShare this page